01 Nov 2017
Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease
20 Nov 2017
Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).
SENIOR, DAPT-STEMI and REDUCE: TCT 2017 Late Breaking Trial Results
01 Nov 2017
Three trials focused on important discussion points for daily practice on the third day of TCT 2017, with two clinical questions in the spotlight: 1) is there still a niche for bare metal stents (BMS) in elderly patients? 2) Is a 12-month duration of DAPT a must-have for all acute coronary syndrome (ACS) patients in the current era?
Results of the 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II Late Breaking Trials: TCT 2017
01 Nov 2017
After the presentation of the data coming from 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II, the interventional cardiology community is even more divided into those in favor or not of Bioresorbable Scaffold (BRS) technology. Many interesting points of discussion arise from these data.
First PIONEER results presenting at TCT
Available to read in EuroIntervention - 2 articles on the PIONEER presented during TCT 2017:
PCR @ TCT 2017
We will be covering a selection of major Late-breaking Clinical Trials in Interventional Cardiology to be released at the 2017 Transcatheter Cardiovascular Therapeutics Scientific Sessions. Get the European Perspective!
ABSORB China: Long term data published in EuroIntervention
26 Oct 2017
Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial
How should I treat an embolised undeployed stent?
03 Oct 2017
A 51-year old man with crescendo angina in background of previous angioplasty to left anterior descending artery and right coronary artery. Coronary angiography demonstrated patent stents, but tight lesion in the distal right coronary artery.
Emergency left main PCI with ‘chimney technique’ to treat coronary artery occlusion after valve-in-valve TAVI
A 77 y/o gentleman with previous aortic valve replacement was referred to our unit to undergo valve-in-valve TAVI for symptomatic bioprosthesis degeneration. His surgical risk was deemed prohibitive due to an infiltrating bowel carcinoma awaiting for surgery…
Evaluation and use of bioresorbable scaffolds for PCI
Five BRS have CE-mark approval for use in Europe. Only one device –the Absorb bioresorbable vascular scaffold– has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years. For this reason, at present BRS should not be preferred to conventional DES in clinical practice. The Task Force recommends that new BRS devices should undergo systematic non-clinical testing according to standardized criteria prior to evaluation in clinical studies. A clinical evaluation plan should include data from a medium sized, randomized trial against DES powered for a surrogate end point of clinical efficacy. Manufacturers of successful devices receive CE- mark approval for use and must have an approved plan for a large-scale randomized clinical trial with planned long-term follow-up.
Magmaris Magnesium BRS: safety and performance of an advanced and innovative technology
16 May 2017 – From EuroPCR 2017
Consult this session presented by M. Joner, W. Wijns and M.K.Y. Lee if you want to find out more about the best indication for patient selection in 2017, ultrathin, bioresorbable polymer sirolimus-eluting stents vs thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisatio; the new update on Dual Antiplatelet Therapy (DAPT) VALIDATE-SWEDEHEART, TROPICAL-ACS and RE-DUAL PCI from the ESC 2017 and more...